Everolimus-induced pneumonitis: Report of the first case in a liver transplant recipient and review of treatment options

Transplant International

Volumn 23, Issue 1, 2010, Pages 110-113

  Schrader, Jörg ^a   Sterneck, Martina ^a   Klose, Hans ^a   Lohse, Ansgar W ^a   Nashan, Björn ^a   Fischer, Lutz ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN;

ALCOHOL LIVER DISEASE; CARDIAC GRAFT REJECTION; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; LETTER; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG BIOPSY; LUNG FUNCTION TEST; PNEUMONIA; PRIORITY JOURNAL;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MIDDLE AGED; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TREATMENT OUTCOME;

EID: 70949090068     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00900.x     Document Type: Letter

References (15)

1. Morard I, Dumortier J, Spahr L, et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007 13 : 658.
2. Gomez-Camarero J, Salcedo M, Rincon D, et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007 84 : 786.
3. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: An overview. Liver Transpl 2001 7 : 473.
4. Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006 12 : 1640. Erratum in: Liver Transpl 2006; 12: 1726.
5. Garrean S, Massad MG, Tshibaka M, Hanhan Z, Caines AE, Benedetti E. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005 19 : 698.
6. Howard L, Gopalan D, Griffiths M, Mahadeva R. Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. Chest 2006 129 : 1718.
7. Roberts RJ, Wells AC, Unitt E, et al. Sirolimus-induced pneumonitis following liver transplantation. Liver Transpl 2007 13 : 853.
8. David S, Kümpers P, Shin H, Haller H, Fliser D. Everolimus- associated interstitial pneumonitis in a patient with a heart transplant. Nephrol Dial Transplant 2007 22 : 3363.
9. Carreño CA, Gadea M. Case report of a kidney transplant recipient converted to everolimus due to malignancy: Resolution of bronchiolitis obliterans organizing pneumonia without everolimus discontinuation. Transplant Proc 2007 39 : 594.
10. Alexandru S, Ortiz A, Baldovi S, et al. Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant 2008 23 : 3353.
11. Expósito V, de Prada JA, Gómez-Román JJ, et al. Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant 2008 27 : 797.
12. Otton J, Hayward CS, Keogh AM, Glanville AR, Macdonald PS. Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant 2009 28 : 104.
13. Morelon E, Stern M, Israël-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001 72 : 787.
14. Weichhart T, Costantino G, Poglitsch M, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008 29 : 565.
15. Schmitz F, Heit A, Dreher S, et al. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol 2008 38 : 2981.